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Vitiligo, the very frequent ancient idiopathic dermatological disorder is characterized by chronic
and progressive autoimmune loss of melanocytes from the basal layers of the epidermis that results
in white macules on the affected skin. Although non-contagious, the phenotype of this disorder has
high impact on the psychological behavior of the affected individuals than their physical ability;
more often lead to social isolation. Over the past decade, the prevalence of vitiligo is on rise, ranges
from 0.5 to 2% worldwide, whereas 0.09 to 8.0% in India (Lu et al., 2007; Shah et al., 2008; Krüger
and Schallreuter, 2012). Because of the intricacy of the disease, although there is a wide range
of treatment modalities available, none of the therapeutic options are effective enough to thwart
further progression or complete cure from depigmentation.
This complex inflammatory disorder involves a combination of pathogenic effects of multiple
susceptible loci and unknown environmental triggers which may act independently or together
in the destruction of melanocytes of the affected area (Le Poole et al., 1993a). Several hypotheses
have been put forward to explain the etio-pathogenesis of this multi-factorial disfiguring disorder,
but are not concrete enough to substantiate the underlying mechanism(s) involved in the disease
development. To recognize genes that mediate in vitiligo susceptibility, diverse approaches such
as gene expression analyses, candidate gene association, genome-wide linkage, and genome wide
association studies have been exploited (Allam and Riad, 2013).
Various studies reported that the initial triggering event of vitiligo is oxidative stress; however,
inflammation and autoimmunity act as major contributors in the pathogenesis, progression and
severity of the disease (Jain et al., 2011; Deo et al., 2013; Laddha et al., 2013; Spritz, 2013). The
autoimmune loss of pigmentation is allied with infiltrates of T cells and macrophages, and the
progression of the disease is due to the decreased CD4+/CD8+ cell ratio which is cytotoxic to
melanocytes (Lili et al., 2012). Animal studies (h3TA2) have further established the fact that
depletion of regulatory T (Treg) cells in knockout mice up regulate the proinflammatory cytokines
and mediate the progressive depigmentation; nevertheless adoptive transfer of Treg cells induce
vitiligo remission in treated mice (Chatterjee et al., 2014).
Treg cells are a unique CD4+ T lymphocyte lineage that plays an indispensable role
in maintaining immunological unresponsiveness to self-antigens and in suppressing excessive
immune responses that are detrimental to the host. Defects in the number and function of
Treg cells in the peripheral blood and lesional skin accentuate the role of Treg cells in vitiligo
pathogenesis (Dwivedi et al., 2015). The crucial master transcription factor that regulates the fate
and identity of Treg cells which play an imperative role in preventing autoimmunity is forkhead
box protein 3 (FOXP3). This key immunoregulatory FOXP3 gene belongs to forkhead/winged-
helix transcription factor family, located at Xp11.23 in humans is 1296 bp in length and consists
of 11 translated exons that encode a protein with 431 amino-acids. It contains a proline rich N-
terminal repressor domain that suppresses the expression of target genes, a zinc-finger (amino
acid 200–223), and leucine-zipper motif (amino acids 240–261) that allow FOXP3 homo- or
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hetero dimerization and a conserved DNA binding forkhead
domain (amino acid 338–421).
FOXP3 gene is vital for the development, proliferation, and
function of CD4+CD25+ Treg cells and therefore essential for
the maintenance of immune homeostasis (Zheng and Rudensky,
2007; Zheng et al., 2007). Alongside the Treg cells development,
FOXP3 gene also has a role in the expression of cytokines
and regulation of other T cell subsets through NF-AT/NF-κB
and Smad7 pathways (Song et al., 2012). Approximately 700
FOXP3 bound genes are up/down regulated in FOXP3+ T cells,
suggesting that FOXP3 acts as both transcriptional activator
and repressor. The functional or quantitative modification of
FOXP3 leads to lack of efficient CD4+CD25+Treg cells, resulting
in immune dysregulation, polyendocrinopathy, enteropathy, X-
linked syndrome (Bennett et al., 2001; Wildin et al., 2002), scurfy
mice and other autoimmune diseases including vitiligo supports
the importance of Treg cells and FOXP3 in keeping autoreactive
T cells in check (Yagi et al., 2004; Lahl et al., 2007).
Comprehensive reanalysis of genome wide data of 33
biological candidate genes previously implicated in generalized
vitiligo (ACE, AIRE, CAT, CD4, CLEC11A, COMT, CTLA4,
C12orf10, DDR1, EDN1, ESR1, FAS, FBXO11, FOXD3, FOXP3,
GSTM1, GSTT1, IL1RN, IL10, KITLG, MBL2, NFE2L2,
PDGFRA-KIT, PTGS2, STAT4, TAP1-PSMB8, TGFBR2, TNF,
TSLP, TXNDC5, UVRAG, VDR, and XBP1) has identified three
candidate genes XBP1, FOXP3, and TSLP in association with
vitiligo that are not shared by other autoimmune diseases (Chen
et al., 2005; Birlea et al., 2010, 2011; Jin et al., 2010; Tang et al.,
2013). Ameta-analysis conducted by Birlea et al. (2010) screening
37 SNPs of FOXP3 gene found greatest significance with a
promoter SNP rs3761547 and strong linkage disequilibrium with
rs11798415 and rs5906843 block; moreover, rs11798415 retained
as a strongest marker than other SNPs (rs11798415, rs5906843,
rs5906777, and rs4824755) in this region. No further studies
are available on FOXP3 gene polymorphisms in relation to
vitiligo, however, in psoriatic patients, one of the upstream SNPs
of FOXP3 gene rs3761548 was found significant association
with the disease (Shen et al., 2010). The study demonstrated
the functional significance of rs3761548 AA genotype which
causes the loss of binding with transcription factors, E47 and
C-Myb, leading to defective transcription of FOXP3. Moreover,
the A allele of this polymorphism is associated with a dramatic
reduction in luciferase activity compared with the C allele (Shen
et al., 2010). Later rs3761548 AA genotype was confirmed to be
the lowest FOXP3 producing genotype and suggested its role in
fewer Treg cells and/or weaker immune suppressive function in
other autoimmune diseases (Wu et al., 2012).
To further evaluate the FOXP3 gene polymorphisms and
their involvement in vitiligo pathogenesis, recent studies from
Indian and Han Chinese populations screened three promoter
SNPs of FOXP3 gene (rs3761548, rs2232365, and rs5902434) and
found significant association of rs3761548 and rs2232365 with
vitiligo risk (Jahan et al., 2013; Song et al., 2013). The rs2232365
polymorphism located within the putative DNA-binding site of
other transcription factor GATA-3, directly regulates FOXP3
expression and controls Treg cell function via interaction with
the regulatory regions of the FOXP3 locus. The GG genotype
of rs2232365 decreases the FOXP3 expression and affects Treg
cell function, thus disrupt the Th1/Th2 balance, leading to the
pro-inflammatory disease vitiligo (Song et al., 2012; Wu et al.,
2012).
Cell based investigations conducted in vitiligo evaluating
quantitative and qualitative analysis of Treg cells in
lesional/perilesional and blood samples had provided mixed
results. According to Zhou et al. (2012) no variation was observed
in systemic Treg cell population between vitiligo patients and
controls. In contrary, it was suggested that the reduced cell
number and impaired function of natural Treg cells is associated
with imbalance of CD4+/CD8+ ratio and was suggested to be
involved in the T-cell mediated pathogenesis of vitiligo and its
progression (Klarquist et al., 2010; Lili et al., 2012; Dwivedi
et al., 2013). At large, most of the investigators implicated the
imbalance in Treg cells in the disease pathogenesis.
Though evidences are mounting toward the involvement
of FOXP3 functional SNPs and quantitative and qualitative
variation of CD4+CD25+Treg cells individually pointing toward
their role in the diseases pathogenesis, studies are lacking to
correlate the FOXP3 gene variants and Treg cell behavior in
vitiligo. It is well established that FOXP3 is a master transcription
factor which influences the quality and quantity of Treg cell
population thus the immune homeostasis of the host. Keeping
in view the pivotal role of Treg cells in the maintenance of
immune balance and association of its master controller FOXP3
gene with autoimmune diseases, in our opinion, FOXP3 is a
potential candidate gene which should be screened thoroughly
for known and novel functional genetic variants and epigenetic
modifications that regulate its expression; further to correlate the
impact of these variations on Treg cell development, stability
and function will be promising in understanding the genetic
heterogeneity of vitiligo. Establishing the role of FOXP3 gene
through family based studies in various ethnic groups will help
in delineating the genetic and non-genetic contributing factors
that are imperative for this multifactorial disorder and also in
understanding the population based variation in its incidence.
Moreover, the interventions targeting Treg cells/FOXP3 gene
networks that could suppress the immune responses may
open new insights for effective therapeutic approaches for
vitiligo.
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